Khadija Mussa Assad
Research Subjects
Khadija Mussa Assad has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Maulid Kombo
Department of Medical Sciences, Jinzhou Medical University , Liaoning
2 shared publications Dongqi Ye
2 shared publications- Fahad Omar Nofli2 shared publications
GangYi Wang
2 shared publicationsHongLi Zhou
2 shared publications- Innocent Tesha
Department of Geriatrics Medicine, First Affiliated Hospital, Jinzhou Medical University , Liaoning
2 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by JMIR Publications Inc. in JMIRx Med
Factors Influencing Hemoglobin Variability and Its Prognostic Implications in Chronic Kidney Disease in dialysis patients. (Preprint)
- 17 March 2026
- Published by JMIR Publications Inc. in JMIRx Med
Open AccessFactors Influencing Hemoglobin Variability and Its Prognostic Implications in Chronic Kidney Disease in dialysis patients. (Preprint)
- Open Access
- 17 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Factors Influencing Hemoglobin Variability and Its Prognostic Implications in Chronic Kidney Disease in dialysis patients. (Preprint)
BACKGROUND Chronic Kidney Disease (CKD) is a global health burden with a high prevalence of anemia, which is largely driven by impaired erythropoiesis due to reduced erythropoietin production, iron deficiency, and chronic inflammation. Hemoglobin variability, defined as fluctuations in hemoglobin levels over time, has emerged as a key factor influencing the prognosis of CKD patients. While anemia is well-recognized in CKD, the implications of hemoglobin variability on patient outcomes, including mortality, cardiovascular events, and hospitalization, remain insufficiently explored. OBJECTIVE Primary Objectives. (1).To identify and quantify factors contributing to hemoglobin variability in CKD patients. (2).To evaluate the relationship between hemoglobin variability and prognosis, including mortality, cardiovascular outcomes, frequency of hospitalization and length of hospital stay. Secondary Objectives. (1).To explore potential strategies for minimizing hemoglobin variability in CKD patients. METHODS This retrospective cohort study aimed to identify the factors that contribute to hemoglobin variability in CKD patients and to assess its relationship with clinical outcomes. By analyzing electronic medical records (EMRs) in The First Affiliated Hospital of Jinzhou Medical University, the study evaluated data from patients with CKD stage 5, including those on dialysis, who had at least 12 months of recorded hemoglobin levels. Different factors were examined to quantify their influence on hemoglobin fluctuations. Also, the study analyzed the relationship between hemoglobin variability and outcomes . RESULTS A total of 504 participants were included. Males were 58.7% and 41.3% females. Over one third of the participants (36.9%) were elderly. Only 3.0% had a hemoglobin that remained in the normal target range (11.0 and 12.5 g/dl) at all measurements done. Majority of the participants (78.4%) had a hemoglobin that remained low (12.5 g/dl). Using the standard deviation, the median variability was 0.56 g/dl, 0.90 g/dl when using absolute range and 6.73% when using coefficient of variation. After categorizing the findings of variability, 30.0% were considered to have high variability which was defined by having variability above the upper quartile using either the standard deviation, the absolute range or the coefficient of variation. In the multivariable analysis, the independent factors contributing to hemoglobin variability in CKD patients were: age below 30 years (aOR=3.557, CI=1.522-8.314, P=0.003), diabetes mellitus (aOR=1.586, CI=1.048-2.401, P=0.029), elevated interleukin 6 (aOR=3.522, CI=1.972-6.289, P<0.001), low albumin (aOR=1.961, CI=1.257-3.060, P=0.003), high CRP (aOR=2.228, CI=1.204-4.125, P=0.011) and low ferritin levels (aOR=3.185, CI=2.019-5.025, P<0.001). Regarding prognosis, a significant association was found regarding mortality, length of hospital stays and frequency of admissions. No significant association was found regarding cardiovascular events. CONCLUSIONS Almost all participants had their Hb levels deranged from the normal target range. Patients below 30 years, those having diabetes mellitus, those with infection, low ferritin or low albumin among CKD patients should be given special attention and care as they are at a higher risk of suffering hemoglobin variation that worsens prognosis. All CKD patients with hemoglobin variability should be followed up more closely to minimize mortality and morbidity, given that it was highly associated with both outcomes .
- 17 March 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFactors Influencing Hemoglobin Variability and Its Prognostic Implications in Chronic Kidney Disease in dialysis patients. (Preprint)
BACKGROUND Chronic Kidney Disease (CKD) is a global health burden with a high prevalence of anemia, which is largely driven by impaired erythropoiesis due to reduced erythropoietin production, iron deficiency, and chronic inflammation. Hemoglobin variability, defined as fluctuations in hemoglobin levels over time, has emerged as a key factor influencing the prognosis of CKD patients. While anemia is well-recognized in CKD, the implications of hemoglobin variability on patient outcomes, including mortality, cardiovascular events, and hospitalization, remain insufficiently explored. OBJECTIVE Primary Objectives. (1).To identify and quantify factors contributing to hemoglobin variability in CKD patients. (2).To evaluate the relationship between hemoglobin variability and prognosis, including mortality, cardiovascular outcomes, frequency of hospitalization and length of hospital stay. Secondary Objectives. (1).To explore potential strategies for minimizing hemoglobin variability in CKD patients. METHODS This retrospective cohort study aimed to identify the factors that contribute to hemoglobin variability in CKD patients and to assess its relationship with clinical outcomes. By analyzing electronic medical records (EMRs) in The First Affiliated Hospital of Jinzhou Medical University, the study evaluated data from patients with CKD stage 5, including those on dialysis, who had at least 12 months of recorded hemoglobin levels. Different factors were examined to quantify their influence on hemoglobin fluctuations. Also, the study analyzed the relationship between hemoglobin variability and outcomes . RESULTS A total of 504 participants were included. Males were 58.7% and 41.3% females. Over one third of the participants (36.9%) were elderly. Only 3.0% had a hemoglobin that remained in the normal target range (11.0 and 12.5 g/dl) at all measurements done. Majority of the participants (78.4%) had a hemoglobin that remained low (12.5 g/dl). Using the standard deviation, the median variability was 0.56 g/dl, 0.90 g/dl when using absolute range and 6.73% when using coefficient of variation. After categorizing the findings of variability, 30.0% were considered to have high variability which was defined by having variability above the upper quartile using either the standard deviation, the absolute range or the coefficient of variation. In the multivariable analysis, the independent factors contributing to hemoglobin variability in CKD patients were: age below 30 years (aOR=3.557, CI=1.522-8.314, P=0.003), diabetes mellitus (aOR=1.586, CI=1.048-2.401, P=0.029), elevated interleukin 6 (aOR=3.522, CI=1.972-6.289, P<0.001), low albumin (aOR=1.961, CI=1.257-3.060, P=0.003), high CRP (aOR=2.228, CI=1.204-4.125, P=0.011) and low ferritin levels (aOR=3.185, CI=2.019-5.025, P<0.001). Regarding prognosis, a significant association was found regarding mortality, length of hospital stays and frequency of admissions. No significant association was found regarding cardiovascular events. CONCLUSIONS Almost all participants had their Hb levels deranged from the normal target range. Patients below 30 years, those having diabetes mellitus, those with infection, low ferritin or low albumin among CKD patients should be given special attention and care as they are at a higher risk of suffering hemoglobin variation that worsens prognosis. All CKD patients with hemoglobin variability should be followed up more closely to minimize mortality and morbidity, given that it was highly associated with both outcomes .